Total Payments
$426,392
2024 Payments
$102,864
Companies
19
Transactions
801
Medicare Patients
1,466
Medicare Billing
$565,671
Payment Breakdown by Category
Consulting$190,564 (44.7%)
Other$151,080 (35.4%)
Travel$58,748 (13.8%)
Food & Beverage$23,218 (5.4%)
Research$2,629 (0.6%)
Education$154.09 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $190,564 | 104 | 44.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $147,380 | 60 | 34.6% |
| Travel and Lodging | $58,748 | 181 | 13.8% |
| Food and Beverage | $23,218 | 445 | 5.4% |
| Honoraria | $3,700 | 2 | 0.9% |
| Unspecified | $2,629 | 4 | 0.6% |
| Education | $154.09 | 5 | 0.0% |
Payments by Type
General
$423,763
797 transactions
Research
$2,629
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| United Therapeutics Corporation | $241,262 | 387 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $87,984 | 227 | $0 (2024) |
| Merck Sharp & Dohme LLC | $26,043 | 35 | $0 (2024) |
| Insmed, Inc. | $14,997 | 18 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14,850 | 17 | $0 (2022) |
| Bayer Healthcare Pharmaceuticals Inc. | $12,337 | 53 | $0 (2024) |
| Actelion Pharmaceuticals, Ltd | $10,150 | 11 | $0 (2017) |
| GlaxoSmithKline, LLC. | $8,202 | 14 | $0 (2020) |
| La Jolla Pharmaceutical Company | $4,786 | 10 | $0 (2021) |
| Genentech, Inc. | $4,256 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $102,864 | 174 | United Therapeutics Corporation ($53,866) |
| 2023 | $81,177 | 172 | United Therapeutics Corporation ($55,986) |
| 2022 | $68,664 | 133 | United Therapeutics Corporation ($40,908) |
| 2021 | $17,008 | 36 | United Therapeutics Corporation ($16,351) |
| 2020 | $10,378 | 21 | GlaxoSmithKline, LLC. ($3,900) |
| 2019 | $53,717 | 73 | United Therapeutics Corporation ($30,522) |
| 2018 | $50,930 | 110 | United Therapeutics Corporation ($29,947) |
| 2017 | $41,655 | 82 | Actelion Pharmaceuticals US, Inc. ($18,480) |
All Payment Transactions
801 individual payment records from CMS Open Payments — Page 1 of 33
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $6,710.00 | General |
| 12/18/2024 | United Therapeutics Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $435.00 | General |
| 12/18/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 12/18/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $36.59 | General |
| Category: Cardiology | ||||||
| 12/12/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $127.32 | General |
| 12/11/2024 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Food and Beverage | In-kind items and services | $32.70 | General |
| Category: Cardio-pulmonary | ||||||
| 12/07/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/06/2024 | Insmed, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,240.00 | General |
| 12/05/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | Cash or cash equivalent | $75.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/04/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | Cash or cash equivalent | $442.03 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/04/2024 | Johnson & Johnson Health Care Systems Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $26.20 | General |
| Category: Cardiology | ||||||
| 12/03/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $30.82 | General |
| Category: Cardiology | ||||||
| 11/20/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $25.12 | General |
| 11/15/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | In-kind items and services | $1,254.67 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | In-kind items and services | $90.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $64.11 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $51.83 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $34.36 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | Cash or cash equivalent | $25.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | In-kind items and services | $221.89 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | In-kind items and services | $220.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/13/2024 | United Therapeutics Corporation | TYVASO (Drug) | Travel and Lodging | Cash or cash equivalent | $80.40 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 312 | 1,090 | $1.2M | $133,308 |
| 2022 | 6 | 361 | 1,200 | $1.4M | $151,705 |
| 2021 | 6 | 327 | 1,077 | $1.1M | $125,666 |
| 2020 | 7 | 466 | 1,214 | $966,333 | $154,992 |
Total Patients
1,466
Total Services
4,581
Medicare Billing
$565,671
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 80 | 378 | $680,400 | $69,017 | 10.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 83 | 344 | $233,920 | $35,008 | 15.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 115 | 328 | $281,424 | $26,256 | 9.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 19 | 25 | $24,000 | $2,747 | 11.4% |
| 94618 | Test for exercise-induced lung stress | Facility | 2023 | 15 | 15 | $6,435 | $280.31 | 4.4% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 93 | 417 | $750,600 | $78,440 | 10.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 81 | 374 | $254,320 | $32,814 | 12.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 83 | 180 | $172,800 | $21,772 | 12.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 79 | 179 | $153,582 | $14,218 | 9.3% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2022 | 13 | 34 | $27,200 | $3,262 | 12.0% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 12 | 16 | $3,998 | $1,200 | 30.0% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 56 | 269 | $484,200 | $51,743 | 10.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 76 | 392 | $266,560 | $34,297 | 12.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 86 | 181 | $173,760 | $22,255 | 12.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 75 | 196 | $168,168 | $16,010 | 9.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 19 | 21 | $10,668 | $1,009 | 9.5% |
| 94618 | Test for exercise-induced lung stress | Facility | 2021 | 15 | 18 | $7,722 | $352.26 | 4.6% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 105 | 492 | $590,400 | $96,123 | 16.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 80 | 237 | $107,835 | $21,562 | 20.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 110 | 224 | $143,360 | $20,402 | 14.2% |
| 99292 | Critical care delivery critically ill or injured patient | Facility | 2020 | 28 | 72 | $38,160 | $7,123 | 18.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 66 | 93 | $53,010 | $6,172 | 11.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 63 | 80 | $32,480 | $3,410 | 10.5% |
| 76937 | Ultrasound guidance for accessing into blood vessel | Facility | 2020 | 14 | 16 | $1,088 | $199.65 | 18.4% |
About Dr. Rajan Saggar, MD
Dr. Rajan Saggar, MD is a Pulmonary Disease healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255351854.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rajan Saggar, MD has received a total of $426,392 in payments from pharmaceutical and medical device companies, with $102,864 received in 2024. These payments were reported across 801 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($190,564).
As a Medicare-enrolled provider, Saggar has provided services to 1,466 Medicare beneficiaries, totaling 4,581 services with total Medicare billing of $565,671. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Internal Medicine
- Location Los Angeles, CA
- Active Since 07/20/2006
- Last Updated 11/23/2010
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1255351854
Products in Payments
- TYVASO (Drug) $99,794
- NONE (Drug) $57,837
- UPTRAVI (Drug) $29,504
- OPSUMIT (Drug) $23,354
- WINREVAIR (Biological) $18,847
- REMODULIN (Drug) $15,425
- Adempas (Drug) $12,337
- ORENITRAM (Drug) $6,332
- GIAPREZA (Drug) $4,741
- Xolair (Biological) $4,216
- OFEV (Drug) $1,731
- FLOWTRIEVER CATHETER, S (Device) $495.43
- OPSUMIT MACITENTAN (Drug) $248.47
- Esbriet (Biological) $187.31
- Prolastin-C (Biological) $178.65
- ULTOMIRIS (Biological) $121.83
- XARELTO (Drug) $103.76
- TREPROSTINIL (Drug) $90.30
- All-In-One (Device) $32.46
- DRAGONFLY OPSTAR (Device) $19.92
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Los Angeles
Prof. Toby Maher, Md, MD
Pulmonary Disease — Payments: $1.1M
Pulmonary Disease $1.1M
Donald Tashkin, Md, MD
Pulmonary Disease — Payments: $646,650
Pulmonary Disease $646,650
John Belperio, Md, MD
Pulmonary Disease — Payments: $308,808
Pulmonary Disease $308,808
Christopher Cooper, Md, MD
Pulmonary Disease — Payments: $207,817
Pulmonary Disease $207,817
Robert Strieter, Md, MD
Pulmonary Disease — Payments: $172,942
Pulmonary Disease $172,942
Roy Artal, M.d, M.D
Pulmonary Disease — Payments: $151,187
Pulmonary Disease $151,187